Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Income from Continuing Operations (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Income from Continuing Operations for 6 consecutive years, with 31946000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 58.02% to 31946000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 113625000.0 through Dec 2025, down 64.69% year-over-year, with the annual reading at 113625000.0 for FY2025, 64.69% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 31946000.0 at Janux Therapeutics, down from 24313000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 2284000.0 in Q1 2021, with the low at 33858000.0 in Q2 2025.
  • Average Income from Continuing Operations over 5 years is 16832150.0, with a median of 16380500.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations tumbled 757.17% in 2021, then skyrocketed 65.96% in 2024.
  • Over 5 years, Income from Continuing Operations stood at 13416000.0 in 2021, then fell by 19.75% to 16065000.0 in 2022, then rose by 26.81% to 11758000.0 in 2023, then crashed by 71.93% to 20216000.0 in 2024, then tumbled by 58.02% to 31946000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 31946000.0, 24313000.0, and 33858000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.